Temporal Trends in Antimicrobial Resistance in a Tertiary Hospital in Western Guangxi, China: A Five-Year Surveillance Study (2021–2025) Authors: Ying Deng, Ying Wei, Yongliang Wang, Xueli Yi, Yuanyuan Dai, Shimao Zhong, Chunhong Liu, YuanJi Teng Published: 2026 ABSTRACT BackgroundAlthough antimicrobial resistance (AMR) exhibits substantial regional heterogeneity, data from western Guangxi in Southwest China remain limited. To address this gap, we conducted a five-year surveillance study at a tertiary hospital in this area to characterize pathogen distribution, resistance trends, and discrepancies compared with national benchmarks.MethodsAll non-duplicate clinical bacterial isolates collected between January 2021, and December 2025 were included. Species identification and antimicrobial susceptibility testing were performed using MALDI-TOF MS and the VITEK 2 system. Results were interpreted according to Clinical and Laboratory Standards Institute (CLSI) criteria. Resistance trends were analyzed using WHONET software, and chi-square tests and trend analyses were applied to evaluate temporal changes and to compare findings with data from the China National Surveillance System (CHINET).ResultsAmong 57,157 clinical isolates, Gram-negative bacteria predominated (71.0%), with Escherichia coli, Klebsiella pneumoniae, and Staphylococcus aureus representing the leading pathogens. ICUs contributed a large share of isolates and showed higher proportions of non-fermentative Gram-negative bacilli and carbapenem-resistant strains, whereas pediatric wards predominantly isolated Haemophilus influenzae and Moraxella catarrhalis. Carbapenem-resistant Escherichia coli (CRECO) and Klebsiella pneumoniae (CRKPN) remained below 5% throughout the study period. In contrast, carbapenem-resistant Pseudomonas aeruginosa (CRPAE) increased from 9.57% in 2021 to 19.96% in 2025. Carbapenem-resistant Acinetobacter baumannii (CRAB) remained highly prevalent (>50% in several years) but declined to 41.53% by 2025. Streptococcus pneumoniae consistently exhibited macrolide resistance rates exceeding 90%. Significant differences compared with CHINET data were observed for CRECO (P=0.043) and CRKPN (P=0.001). The local prevalence of CRECO and respiratory pathogens significantly exceeded national CHINET data, while CRKPN prevalence was comparatively lower.ConclusionThis study describes antimicrobial resistance patterns in a tertiary hospital in western Guangxi, China, with an increasing trend in CRPAE, while CRECO remained below 5% but was relatively higher than that reported in CHINET data, warranting continued surveillance. These findings underscore the essential role of regional surveillance and highlight the need for continued monitoring and strengthened antimicrobial stewardship, particularly in ICU settings and pediatric respiratory infections. Introduction Antimicrobial resistance (AMR) is a major global public health challenge, associated with increased morbidity, mortality, and healthcare costs worldwide. According to the Global Burden of Bacterial Resistance study, approximately 1.27 million people died directly from drug-resistant bacterial infections worldwide in 2019, with related deaths totaling nearly 5 million.1 This makes bacterial resistance a leading cause of death worldwide. The rapid spread of multidrug-resistant organisms (MDROs), particularly carbapenem-resistant Gram-negative bacteria, poses a substantial challenge to modern healthcare systems.2 China bears a heavy burden of antimicrobial resistance due to its large population, significant disparities in healthcare conditions, and historical high levels of antibiotic consumption.3 In China, national surveillance programs such as CARSS and CHINET have reported increasing resistance among key pathogens, highlighting substantial regional variability.4 However, substantial regional heterogeneity persists, driven by differences in antimicrobial use and stewardship, local patient case-mix, and the effectiveness of infection prevention and control practices.5 Therefore, a systematic analysis of bacterial resistance is crucial for accurately characterizing local epidemiological patterns and complementing national surveillance data. The World Health Organization recognizes carbapenem-resistant organisms, including carbapenem-resistant Enterobacterales (CRE), CRAB and CRPAE, as critical priority pathogens due to their high mortality rates and limited treatment options.6 These pathogens are closely associated with high mortality rates, prolonged hospital stays, and limited treatment options.7–9 Meanwhile, the increasing resistance of community-acquired respiratory pathogens—including Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis—continues to complicate empirical treatment strategies, particularly in pediatric populations.10 Compared with the more economically developed eastern coastal regions of China, western Guangxi remains less developed both economically and geographically, resulting in limited published data on antimicrobial resistance.11 Large tertiary hospitals in this region serve a diverse patient population, including critically ill individuals in ICUs and a large number of pediatric patients. These characteristics may shape distinctive resistance patterns that are not fully captured by national aggregate data.11 The data from western Guangxi, a less well-represented region, remain limited. Therefore, surveillance in this setting can provide insight into local epidemiological patterns and help guide antibiotic use. This study examined the distribution of clinical bacterial isolates in a large tertiary hospital in Southwest China from 2021 to 2025. Changes in antimicrobial resistance were also evaluated, with a focus on carbapenem-resistant organisms, and the results were compared with national CHINET data. By identifying local variations relative to national benchmarks, the study will provide evidence to inform the development of targeted antimicrobial stewardship and infection control strategies. Materials and Methods Study Setting and Study Population This study was conducted at the Affiliated Hospital of Youjiang Medical University for Nationalities in Baise, Guangxi Zhuang Autonomous Region, Southwest China. The hospital is a tertiary Grade A teaching hospital with approximately 3100 beds and 37 specialized departments, including intensive care and pediatric units. It serves as a regional referral center for the Guangxi, Yunnan and Guizhou border region. Study participants included both inpatients and outpatients, including those referred from surrounding healthcare facilities. Approximately 90% of the clinical isolates were derived from inpatient specimens, while the remaining 10% were obtained from outpatient settings. Clinical specimens were collected as part of routine clinical care and included samples from the respiratory tract, blood, urine, and other body sites, representing a broad range of clinical conditions. Bacterial Isolates All clinical bacterial isolates were collected from all clinical specimens obtained between January 2021 and December 2025. Duplicate isolates from the same site or patient were excluded. All specimens were processed according to standard microbiological protocols. Identification and Antimicrobial Susceptibility Testing Bacterial identification and antimicrobial susceptibility testing were performed using matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) and the VITEK 2 Compact system (bioMérieux, France). The antibiotic susceptibility test (AST) cards used included AST-GN13, AST-GN09, AST-N334, AST-N335, AST-P639, AST-GP68 and AST-GP67. Antimicrobial susceptibility results were interpreted according to Clinical and Laboratory Standards Institute (CLSI) guidelines (2025 edition). CRE were defined as isolates of Escherichia coli, Klebsiella pneumoniae, or other Enterobacterales that were resistant to at least one carbapenem (imipenem, meropenem, or ertapenem) according to CLSI criteria. CRPAE and CRAB were defined as isolates resistant to imipenem and/or meropenem. MRSA was defined as isolates resistant to oxacillin. Vancomycin-resistant enterococci (VRE) were defined as Enterococcus faecalis or Enterococcus faecium isolates resistant to vancomycin. For each organism, annual resistance rates were calculated using the total number of isolates of the same species in the corresponding year as the denominator. Quality Control and Data Analysis Quality control was performed in accordance with routine clinical microbiology laboratory procedures. Reference strains Escherichia coli ATCC 25922, Staphylococcus aureus ATCC 29213, and Pseudomonas aeruginosa ATCC 27853 were used for quality control. All quality control results were required to fall within the acceptable ranges defined by CLSI guidelines before test results were included in the analysis. Data were extracted from the hospital microbiology laboratory information system and imported into WHONET for analysis. Duplicate isolates were excluded according to the predefined rule that only the first isolate of the same bacterial species recovered from the same patient and specimen site during the study period was included. Annual resistance rates were calculated using the total number of isolates of the corresponding species tested in each year as the denominator. Resistance rates and pathogen distribution were analyzed on an annual basis for each year from 2021 to 2025 to assess temporal trends over the entire study period. The data analysis in this study provides a comprehensive and independent assessment of antimicrobial resistance trends across the entire institution. This dataset has not been previously published. Statistical Analysis Resistance rates were calculated using the total number of isolates of the corresponding species in each year as the denominator. Resistance trends were analyzed using WHONET software. Chi-square tests were used to compare differences in resistance rates and pathogen detection rates between groups or across years, where appropriate. Cohen’s d was calculated to estimate the magnitude of differences in selected comparisons. P <0.05 was considered statistically significant. Results Annual Distribution of Pathogenic Bacteria A total of 57,157 bacterial strains were isolated between 2021 and 2025. The majority of isolates were obtained from endotracheal aspirates (ETAs) and Bronchoalveolar lavage fluid (BALF) (40.9%), urine (13.49%), secretions (11.54%), blood (11.17%) (Table 1). Gram-negative bacteria accounted for 40,587 isolates (71.01%), whereas Gram-positive organisms comprised 16,570 isolates (28.99%). Among Gram-negative pathogens, the five most frequently identified species were Escherichia coli (14.68%), Klebsiella pneumoniae (14.18%), Haemophilus influenzae (8.54%), Pseudomonas aeruginosa (7.9%), and Acinetobacter baumannii (6.09%). The top five Gram-positive bacteria were Staphylococcus aureus (10.7%), Streptococcus pneumoniae (5.63%), coagulase-negative staphylococci (5.11%), Streptococcus agalactiae (2.33%) and Enterococcus faecalis (1.73%) (Table 2). Over the five-year period, pediatric wards and the ICUs were the primary areas for pathogen detection (Table 3). In the ICU, Acinetobacter baumannii dominated in 2021 and 2022, while Klebsiella pneumoniae became predominant from 2023 to 2025. In non-ICU departments, Escherichia coli was the most common isolated strain (Table 4). Pediatric isolates were predominantly respiratory pathogens. Haemophilus influenzae accounted for 83.96% (4099/4882) of all isolates of this species, Moraxella catarrhalis for 86.85% (2887/3324), and Streptococcus pneumoniae for 85.83% (2761/3217) (Table 5).Table 1Distribution of Clinical SpecimensYear (n)Type of Specimen2021 (n=7874)2022 (n=9233)2023 (n=13312)2024 (n=13344)2025 (n=13394)Total (n=57157)n%n%n%n%n%n%BALF and ETAs322140.90387842.00628647.225904.844.25580043.3025,09043.90Urine109213.87137114.85141010.59175513.15208415.56771213.49Secretion111214.12119912.99133110.00163112.2213249.89659711.54Blood81410.3493710.15166212.4812909.67167912.54638211.17Sputum80510.2396910.50157211.81147611.06145010.83627210.97Body fluids2733.477027.608056.058136.098086.0334015.95Other5577.071771.922461.854743.552491.8617032.98Total7874100923310013,31210013,34410013,39410057,157100Notes: Other, specimen not on the list. Body fluids include pleural fluid, ascitic fluid, cerebrospinal fluid, and other effusion specimens.Abbreviations: ETAs, endotracheal aspirates; BALF, Bronchoalveolar lavage fluid; n, the number of strains. Table 2Distribution and Proportion of Major Bacterial Isolates, 2021–2025Year (n)Pathogenic Bacteria2021 (n=7874)2022 (n=9233)2023 (n=13312)2024 (n=13344)2025 (n=13394)Total (n=57157)n%n%n%n%n%n%Gram-negative bacteria544169.10643469.68936070.31968372.56966972.1940,58771.01Escherichia coli122915.61137514.89179813.51190614.28208315.55839114.68Klebsiella pneumoniae86210.95124313.46188414.15205415.39206115.39810414.18Haemophilus influenzae6868.717267.8611368.5313249.9210107.5448828.54Pseudomonas aeruginosa5547.047327.9311358.5310888.1510077.5245167.90Acinetobacter baumannii4996.346547.089627.238166.125494.1034806.09Moraxella catarrhalis5306.735255.698656.505754.318296.1933245.82Stenotrophomonas maltophilia2322.952452.653482.614113.084743.5417102.99Enterobacter cloacae2142.722522.733492.623782.833582.6715512.71Serratia marcescens750.951121.211010.761931.451631.226441.13Klebsiella aerogenes780.99660.71980.741320.991431.075170.90Others4826.125045.466845.148066.049927.4134686.07Gram-positive bacteria243330.90279930.32395229.69366127.44372527.8116,57028.99Staphylococcus aureus89411.359159.91154511.61144010.7913219.86611510.70Streptococcus pneumoniae5316.746336.868986.755854.385704.2632175.63Coagulase negative staphylococcus4055.145325.766434.836705.026684.9929185.11Streptococcus agalactiae1451.841811.962141.612311.732171.6213332.33Enterococcus faecalis2072.632312.502621.972842.133492.619881.73Enterococcus faecium730.931101.191220.921331.001591.195971.04Others1782.261972.132682.013182.384413.2914022.452Total7874100923310013,31210013,34410013,39410057,157100Note: Other, bacteria not on the list. Table 3Top 10 Hospital Departments by Pathogen Detection Rate20212022202320242025Clinical Departmentn=7874%Clinical Departmentn=9233%Clinical Departmentn=13312%Clinical Departmentn=13344%Clinical Departmentn=13394%Department of Pediatrics195224.79Department of Pediatrics216223.42Department of Pediatrics356826.80Department of Pediatrics321224.07Department of Pediatrics292121.81ICU128516.32ICU138114.96ICU173013.00ICU172812.95ICU149511.16Department of Urology5396.85Department of Respiratory and Critical Care Medicine6386.91Department of Urology8136.11Department of Urology9587.18Department of Urology9537.12Department of Gastroenterology3394.31Department of Urology6146.65Department of Respiratory and Critical Care Medicine7365.53Department of Respiratory and Critical Care Medicine8566.41Department of Respiratory and Critical Care Medicine8776.55Department of Nephrology3324.22Department of Nephrology3363.64Department of Gastroenterology4463.35Department of Gastroenterology4903.67Department of Nephrology5504.11Department of Respiratory and Critical Care Medicine2863.63Department of Gastroenterology2963.21Department of Nephrology3862.90Department of Nephrology4433.32Department of Gastroenterology4923.67Department of Hand and Foot Surgery2503.18Department of Infectious Diseases2282.47Department of Infectious Diseases3152.37Department of Infectious Diseases3352.51Department of Infectious Diseases4263.18Department of Burns and Plastic Surgery1832.32Department of Rehabilitation Medicine1791.94Department of Burns and Plastic Surgery2141.61Department of Burns and Plastic Surgery2321.74Department of Neurosurgery3402.54Department of Dermatology1722.18Department of Endocrinology1761.91Department of Neurosurgery2121.59Department of Dermatology2181.63Department of Endocrinology2481.85Department of Rehabilitation Medicine1501.91Department of Burns and Plastic Surgery1711.85Department of Endocrinology2021.52Department of Neurosurgery1991.49Department of Dermatology2421.81 Table 4Distribution of Bacterial Isolates in ICU and Non-ICU DepartmentsClinical DepartmentYear (n)Pathogenic BacteriaICUNon-ICUICUNon-ICUICUNon-ICUICUNon-ICUICUNon-ICU2021 (n=1285)2021 (n=6589)2022 (n=1381)2022 (n=7852)2023 (n=1730)2023 (n=11582)2024 (n=1728)2024 (n=11616)2025 (n=1495)2025 (n=11899)n%n%n%n%n%n%n%n%n%n%Gram-negative bacteria93973.07448568.07101473.43540268.80125872.72808369.79125572.63840672.37107171.64857672.07Acinetobacter baumannii24619.142854.3325018.104695.9733119.137076.1022112.796385.491097.294603.87Klebsiella pneumoniae23918.606399.7024918.03102913.1034319.83159013.7335120.31174815.0531320.94179515.09Stenotrophomonas maltophilia1189.181281.94946.811672.13714.102872.481307.522992.571338.903593.02Escherichia coli1088.40114117.321299.34127716.261327.63167814.491377.93179415.441298.63197416.59Pseudomonas aeruginosa886.854837.331138.186578.371176.7610408.981398.049868.491157.699277.79Klebsiella aerogenes262.02540.82151.09540.69160.92840.73331.911010.87402.681070.90Enterobacter cloacae201.561952.96251.812302.93372.143132.70512.953312.85322.143282.76Haemophilus influenzae151.1767110.18332.396948.84593.4110779.30704.05125710.82382.549748.19Moraxella catarrhalis40.315267.98282.034976.33714.107966.87130.755624.84312.077986.71Burkholderia sp.141.0940.06110.80130.1790.52130.11201.16350.30281.87490.41Elizabethkingia meningoseptica100.7860.0920.1480.10110.64160.14100.58190.1690.60260.22Other513.973535.36654.713073.91613.534824.16804.636365.48946.297796.55Gram-positive bacteria34626.93210431.9336726.57245031.2047227.28349930.2147327.37321027.6342428.36332327.93Staphylococcus aureus13710.6677011.691118.0481410.3721412.37134311.601659.55129011.111228.16120910.16Coagulase negative staphylococcus15211.832543.8517612.743604.581649.484754.1022513.024473.8522915.324463.75Streptococcus pneumoniae90.705247.95282.036087.74563.248457.30241.395624.84231.545484.61Streptococcus agalactiae90.701362.0620.141792.2820.122121.8380.462231.9230.202141.80Enterococcus faecalis161.251912.90181.302142.7360.352582.23110.642732.3590.603402.86Enterococcus faecium60.47671.02141.01971.24160.921060.92181.041181.02171.141441.21Other171.321622.46181.301782.27140.812602.24221.272972.56211.404223.551285100658910013811007852100173010011,582100172810011,616100149510011,899100Note: Other, bacteria not on the list. Table 5Distribution of Major Bacterial Isolates in Pediatric DepartmentsYear (n)Pathogenic Bacteria2021 (n=1952)2022 (n=2162)2023 (n=3568)2024 (n=3212)2025 (n=2921)Total (n=13815)n%n%n%n%n%n%Haemophilus influenzae60931.2059227.3896927.16109634.1283328.52409929.67Moraxella catarrhalis48324.7445320.9573320.5451716.1070124.00288720.90Streptococcus pneumoniae46924.0353524.7574420.8552716.4148616.64276119.99Staphylococcus aureus1447.3822710.5047113.2039612.3329910.24153711.13Escherichia coli673.43823.791393.901354.201334.555564.02Klebsiella pneumoniae392.00894.121343.761604.981073.665293.83Pseudomonas aeruginosa351.79673.101323.701153.58712.434203.04Other1065.431175.412466.892668.282919.9610267.43Total1952100216210035681003212100292110013,815100Note: Other, bacteria not on the list. Table 1Distribution of Clinical SpecimensYear (n)Type of Specimen2021 (n=7874)2022 (n=9233)2023 (n=13312)2024 (n=13344)2025 (n=13394)Total (n=57157)n%n%n%n%n%n%BALF and ETAs322140.90387842.00628647.225904.844.25580043.3025,09043.90Urine109213.87137114.85141010.59175513.15208415.56771213.49Secretion111214.12119912.99133110.00163112.2213249.89659711.54Blood81410.3493710.15166212.4812909.67167912.54638211.17Sputum80510.2396910.50157211.81147611.06145010.83627210.97Body fluids2733.477027.608056.058136.098086.0334015.95Other5577.071771.922461.854743.552491.8617032.98Total7874100923310013,31210013,34410013,39410057,157100Notes: Other, specimen not on the list. Body fluids include pleural fluid, ascitic fluid, cerebrospinal fluid, and other effusion specimens.Abbreviations: ETAs, endotracheal aspirates; BALF, Bronchoalveolar lavage fluid; n, the number of strains. Distribution of Clinical Specimens Notes: Other, specimen not on the list. Body fluids include pleural fluid, ascitic fluid, cerebrospinal fluid, and other effusion specimens. Abbreviations: ETAs, endotracheal aspirates; BALF, Bronchoalveolar lavage fluid; n, the number of strains. Table 2Distribution and Proportion of Major Bacterial Isolates, 2021–2025Year (n)Pathogenic Bacteria2021 (n=7874)2022 (n=9233)2023 (n=13312)2024 (n=13344)2025 (n=13394)Total (n=57157)n%n%n%n%n%n%Gram-negative bacteria544169.10643469.68936070.31968372.56966972.1940,58771.01Escherichia coli122915.61137514.89179813.51190614.28208315.55839114.68Klebsiella pneumoniae86210.95124313.46188414.15205415.39206115.39810414.18Haemophilus influenzae6868.717267.8611368.5313249.9210107.5448828.54Pseudomonas aeruginosa5547.047327.9311358.5310888.1510077.5245167.90Acinetobacter baumannii4996.346547.089627.238166.125494.1034806.09Moraxella catarrhalis5306.735255.698656.505754.318296.1933245.82Stenotrophomonas maltophilia2322.952452.653482.614113.084743.5417102.99Enterobacter cloacae2142.722522.733492.623782.833582.6715512.71Serratia marcescens750.951121.211010.761931.451631.226441.13Klebsiella aerogenes780.99660.71980.741320.991431.075170.90Others4826.125045.466845.148066.049927.4134686.07Gram-positive bacteria243330.90279930.32395229.69366127.44372527.8116,57028.99Staphylococcus aureus89411.359159.91154511.61144010.7913219.86611510.70Streptococcus pneumoniae5316.746336.868986.755854.385704.2632175.63Coagulase negative staphylococcus4055.145325.766434.836705.026684.9929185.11Streptococcus agalactiae1451.841811.962141.612311.732171.6213332.33Enterococcus faecalis2072.632312.502621.972842.133492.619881.73Enterococcus faecium730.931101.191220.921331.001591.195971.04Others1782.261972.132682.013182.384413.2914022.452Total7874100923310013,31210013,34410013,39410057,157100Note: Other, bacteria not on the list. Distribution and Proportion of Major Bacterial Isolates, 2021–2025 Note: Other, bacteria not on the list. Table 3Top 10 Hospital Departments by Pathogen Detection Rate20212022202320242025Clinical Departmentn=7874%Clinical Departmentn=9233%Clinical Departmentn=13312%Clinical Departmentn=13344%Clinical Departmentn=13394%Department of Pediatrics195224.79Department of Pediatrics216223.42Department of Pediatrics356826.80Department of Pediatrics321224.07Department of Pediatrics292121.81ICU128516.32ICU138114.96ICU173013.00ICU172812.95ICU149511.16Department of Urology5396.85Department of Respiratory and Critical Care Medicine6386.91Department of Urology8136.11Department of Urology9587.18Department of Urology9537.12Department of Gastroenterology3394.31Department of Urology6146.65Department of Respiratory and Critical Care Medicine7365.53Department of Respiratory and Critical Care Medicine8566.41Department of Respiratory and Critical Care Medicine8776.55Department of Nephrology3324.22Department of Nephrology3363.64Department of Gastroenterology4463.35Department of Gastroenterology4903.67Department of Nephrology5504.11Department of Respiratory and Critical Care Medicine2863.63Department of Gastroenterology2963.21Department of Nephrology3862.90Department of Nephrology4433.32Department of Gastroenterology4923.67Department of Hand and Foot Surgery2503.18Department of Infectious Diseases2282.47Department of Infectious Diseases3152.37Department of Infectious Diseases3352.51Department of Infectious Diseases4263.18Department of Burns and Plastic Surgery1832.32Department of Rehabilitation Medicine1791.94Department of Burns and Plastic Surgery2141.61Department of Burns and Plastic Surgery2321.74Department of Neurosurgery3402.54Department of Dermatology1722.18Department of Endocrinology1761.91Department of Neurosurgery2121.59Department of Dermatology2181.63Department of Endocrinology2481.85Department of Rehabilitation Medicine1501.91Department of Burns and Plastic Surgery1711.85Department of Endocrinology2021.52Department of Neurosurgery1991.49Department of Dermatology2421.81 Top 10 Hospital Departments by Pathogen Detection Rate Table 4Distribution of Bacterial Isolates in ICU and Non-ICU DepartmentsClinical DepartmentYear (n)Pathogenic BacteriaICUNon-ICUICUNon-ICUICUNon-ICUICUNon-ICUICUNon-ICU2021 (n=1285)2021 (n=6589)2022 (n=1381)2022 (n=7852)2023 (n=1730)2023 (n=11582)2024 (n=1728)2024 (n=11616)2025 (n=1495)2025 (n=11899)n%n%n%n%n%n%n%n%n%n%Gram-negative bacteria93973.07448568.07101473.43540268.80125872.72808369.79125572.63840672.37107171.64857672.07Acinetobacter baumannii24619.142854.3325018.104695.9733119.137076.1022112.796385.491097.294603.87Klebsiella pneumoniae23918.606399.7024918.03102913.1034319.83159013.7335120.31174815.0531320.94179515.09Stenotrophomonas maltophilia1189.181281.94946.811672.13714.102872.481307.522992.571338.903593.02Escherichia coli1088.40114117.321299.34127716.261327.63167814.491377.93179415.441298.63197416.59Pseudomonas aeruginosa886.854837.331138.186578.371176.7610408.981398.049868.491157.699277.79Klebsiella aerogenes262.02540.82151.09540.69160.92840.73331.911010.87402.681070.90Enterobacter cloacae201.561952.96251.812302.93372.143132.70512.953312.85322.143282.76Haemophilus influenzae151.1767110.18332.396948.84593.4110779.30704.05125710.82382.549748.19Moraxella catarrhalis40.315267.98282.034976.33714.107966.87130.755624.84312.077986.71Burkholderia sp.141.0940.06110.80130.1790.52130.11201.16350.30281.87490.41Elizabethkingia meningoseptica100.7860.0920.1480.10110.64160.14100.58190.1690.60260.22Other513.973535.36654.713073.91613.534824.16804.636365.48946.297796.55Gram-positive bacteria34626.93210431.9336726.57245031.2047227.28349930.2147327.37321027.6342428.36332327.93Staphylococcus aureus13710.6677011.691118.0481410.3721412.37134311.601659.55129011.111228.16120910.16Coagulase negative staphylococcus15211.832543.8517612.743604.581649.484754.1022513.024473.8522915.324463.75Streptococcus pneumoniae90.705247.95282.036087.74563.248457.30241.395624.84231.545484.61Streptococcus agalactiae90.701362.0620.141792.2820.122121.8380.462231.9230.202141.80Enterococcus faecalis161.251912.90181.302142.7360.352582.23110.642732.3590.603402.86Enterococcus faecium60.47671.02141.01971.24160.921060.92181.041181.02171.141441.21Other171.321622.46181.301782.27140.812602.24221.272972.56211.404223.551285100658910013811007852100173010011,582100172810011,616100149510011,899100Note: Other, bacteria not on the list. Distribution of Bacterial Isolates in ICU and Non-ICU Departments Note: Other, bacteria not on the list. Table 5Distribution of Major Bacterial Isolates in Pediatric DepartmentsYear (n)Pathogenic Bacteria2021 (n=1952)2022 (n=2162)2023 (n=3568)2024 (n=3212)2025 (n=2921)Total (n=13815)n%n%n%n%n%n%Haemophilus influenzae60931.2059227.3896927.16109634.1283328.52409929.67Moraxella catarrhalis48324.7445320.9573320.5451716.1070124.00288720.90Streptococcus pneumoniae46924.0353524.7574420.8552716.4148616.64276119.99Staphylococcus aureus1447.3822710.5047113.2039612.3329910.24153711.13Escherichia coli673.43823.791393.901354.201334.555564.02Klebsiella pneumoniae392.00894.121343.761604.981073.665293.83Pseudomonas aeruginosa351.79673.101323.701153.58712.434203.04Other1065.431175.412466.892668.282919.9610267.43Total1952100216210035681003212100292110013,815100Note: Other, bacteria not on the list. Distribution of Major Bacterial Isolates in Pediatric Departments Note: Other, bacteria not on the list. Antimicrobial Resistance in Gram-Positive Bacteria Methicillin-Resistant and Methicillin-Susceptible Staphylococcus aureus During the five-year study period (2021–2025), no S. aureus isolates exhibited resistance to vancomycin, linezolid, or tigecycline. Compared with methicillin-susceptible S. aureus (MSSA), methicillin-resistant S. aureus (MRSA) demonstrated significantly higher resistance to multiple antimicrobial agents. Resistance to clindamycin, erythromycin, and tetracycline was markedly higher in MRSA isolates (all P < 0.001), with very large effect sizes (Cohen’s d > 5.0). Similarly, resistance to gentamicin (P = 0.010), rifampicin (P = 0.004), ciprofloxacin (P = 0.020), and levofloxacin (P = 0.022) was significantly greater among MRSA isolates, all exhibiting large effect sizes (Cohen’s d > 2.0) (Table 6). For certain organism–antibiotic combinations, no resistant isolates were detected in this study, resulting in a reported resistance rate of 0%. These findings should be interpreted with caution. The same explanation applies to other 0% resistance results reported here.Table 6Antimicrobial Resistance Rates of Staphylococcus aureus Isolates (%)Bacteria YearAntibioticsMRSAMSSAtPCohen’s d2021(n=261)2022(n=272)2023(n=438)2024(n=387)2025(n=324)2021(n=633)2022(n=643)2023(n=1107)2024(n=1053)2025(n=997)Penicillin G10010010010010083.9286.4684.1486.5986.99NANANAOxacillin10010010010010000000NANANAGentamicin4.214.783.888.276.172.981.391.622.072.114.0390.0102.55Rifampicin4.602.573.204.915.860.940.620.631.040.605.7520.0043.64Ciprofloxacin8.0510.2910.5017.0513.897.545.085.426.217.123.4480.0202.18Levofloxacin8.0510.2910.0517.0513.897.545.085.426.126.823.4080.0222.16Clindamycin63.2249.2658.6855.4458.0210.529.557.5810.588.0320.0900.00112.71Erythromycin75.8673.9079.4578.5573.1529.3624.9623.5628.2523.2728.6720.00118.13Tetracycline60.1548.9052.9753.4951.5436.4231.5930.5134.8432.509.3930.0015.94TMP–SMX8.058.0910.5010.399.668.326.788.228.119.071.8960.0991.20Linezolid0000000000NANANAVancomycin0000000000NANANATigecycline0000000000NANANAQuinupristin/Dalfopristin0000000000NANANAAbbreviations: NA, not applicable; TMP–SMX, trimethoprim–sulfamethoxazole. Table 6Antimicrobial Resistance Rates of Staphylococcus aureus Isolates (%)Bacteria YearAntibioticsMRSAMSSAtPCohen’s d2021(n=261)2022(n=272)2023(n=438)2024(n=387)2025(n=324)2021(n=633)2022(n=643)2023(n=1107)2024(n=1053)2025(n=997)Penicillin G10010010010010083.9286.4684.1486.5986.99NANANAOxacillin10010010010010000000NANANAGentamicin4.214.783.888.276.172.981.391.622.072.114.0390.0102.55Rifampicin4.602.573.204.915.860.940.620.631.040.605.7520.0043.64Ciprofloxacin8.0510.2910.5017.0513.897.545.085.426.217.123.4480.0202.18Levofloxacin8.0510.2910.0517.0513.897.545.085.426.126.823.4080.0222.16Clindamycin63.2249.2658.6855.4458.0210.529.557.5810.588.0320.0900.00112.71Erythromycin75.8673.9079.4578.5573.1529.3624.9623.5628.2523.2728.6720.00118.13Tetracycline60.1548.9052.9753.4951.5436.4231.5930.5134.8432.509.3930.0015.94TMP–SMX8.058.0910.5010.399.668.326.788.228.119.071.8960.0991.20Linezolid0000000000NANANAVancomycin0000000000NANANATigecycline0000000000NANANAQuinupristin/Dalfopristin0000000000NANANAAbbreviations: NA, not applicable; TMP–SMX, trimethoprim–sulfamethoxazole. Antimicrobial Resistance Rates of Staphylococcus aureus Isolates (%) Abbreviations: NA, not applicable; TMP–SMX, trimethoprim–sulfamethoxazole. Antimicrobial Resistance in Streptococcus pneumoniae From 2021 to 2025, Streptococcus pneumoniae exhibited persistently high resistance to erythromycin, clindamycin, and tetracycline. Oxacillin resistance increased steadily over the study period, indicating a rising proportion of penicillin-non-susceptible Streptococcus pneumoniae. Resistance to cefuroxime, ceftriaxone, and meropenem remained at moderate levels with annual fluctuations. Notably, no resistant strains to linezolid or vancomycin were detected throughout the five-year period, and the resistance to levofloxacin remained consistently low, suggesting the sustained in vitro activity of these drugs (Table 7).Table 7Antimicrobial Resistance Rates of Streptococcus pneumoniae Isolates (%)YearAntibiotics2021(n=531)2022(n=633)2023(n=898)2024(n=585)2025(n=570)Penicillin G1.601.731.642.282.39Oxacillin60.6061.9066.3069.7072.40Amoxicillin–clavulanic acid0.560.980.771.142.13Cefuroxime57.2162.8865.3169.0768.29Ceftriaxone15.1117.7314.2716.3218.3Meropenem24.8620.0014.8217.6418.23Levofloxacin0.40.340.120.20TMP–SMX5453.3850.5453.4547.17Clindamycin91.1193.2092.4794.3093.08Erythromycin97.3596.8896.0998.1198.34Linezolid00000Vancomycin00000Chloramphenicol5.796.174.684.253.96Tetracycline92.8789.6989.8491.5690.28 Table 7Antimicrobial Resistance Rates of Streptococcus pneumoniae Isolates (%)YearAntibiotics2021(n=531)2022(n=633)2023(n=898)2024(n=585)2025(n=570)Penicillin G1.601.731.642.282.39Oxacillin60.6061.9066.3069.7072.40Amoxicillin–clavulanic acid0.560.980.771.142.13Cefuroxime57.2162.8865.3169.0768.29Ceftriaxone15.1117.7314.2716.3218.3Meropenem24.8620.0014.8217.6418.23Levofloxacin0.40.340.120.20TMP–SMX5453.3850.5453.4547.17Clindamycin91.1193.2092.4794.3093.08Erythromycin97.3596.8896.0998.1198.34Linezolid00000Vancomycin00000Chloramphenicol5.796.174.684.253.96Tetracycline92.8789.6989.8491.5690.28 Antimicrobial Resistance Rates of Streptococcus pneumoniae Isolates (%) Antimicrobial Resistance in Enterococcus spp Between 2021 and 2025, Enterococcus faecalis maintained high susceptibility to β-lactam antibiotics, with resistance to penicillin G and ampicillin consistently below 4%. Conversely, Enterococcus faecium exhibited persistently high resistance exceeding 70% to these agents, surpassing 90% in certain years. High-level aminoglycoside resistance was observed in both species. E. faecium demonstrated particularly elevated resistance to high-level gentamicin, reaching 58.49% in 2025, whereas E. faecalis showed fluctuating but sustained resistance of approximately 30–40%. Compared to E. faecalis (approximately 22–36%), E. faecium exhibits higher resistance to fluoroquinolones (approximately 70–87%). Resistance to macrolides and tetracyclines remained persistently high in both strains: E. faecalis exhibited erythromycin resistance exceeding 50%, while E. faecium reached approximately 80%. Tetracycline resistance surpassed 80% in most years. Quinupristin/dalfopristin retains potent activity against E. faecium (< 5%), but its activity against E. faecalis is significantly reduced (approximately 52–67%). No resistance to linezolid, vancomycin, or tigecycline was detected in either species during the five-year period (Table 8).Table 8Antimicrobial Resistance Rates of E. Faecalis and E. Faecium Isolates (%)BacteriaAntibioticsE. faecalisE. faecium2021(n=207)2022(n=231)2023(n=262)2024(n=284)2025(n=349)2021(n=73)2022(n=110)2023(n=122)2024(n=133)2025(n=159)Penicillin G3.381.301.923.523.1584.9374.5584.3092.4289.31Ampicillin2.420.871.153.172.0179.4569.0979.5190.1586.79Gentamicin-high34.4729.8735.1133.1039.6653.4246.3650.0038.6458.49Streptomycin24.5125.6520.0026.0632.7627.4032.7333.6143.5133.96Ciprofloxacin-high24.1523.0426.5427.4635.5378.0870.0077.6987.1284.28Levofloxacin23.1922.6125.3826.0634.1075.3469.0976.8686.3684.28Erythromycin52.1754.3557.6356.3459.3182.1981.8279.3487.1279.87Nitrofurantoin0.491.731.151.411.7263.0151.8259.5067.4458.49Tetracycline77.7880.0085.8287.6885.1083.5671.8280.3391.6783.65Quinupristin/Dalfopristin76.8151.3069.2367.2569.9104.554.963.794.40Linezolid0000000000Vancomycin0000000000Tigecycline0000000000 Table 8Antimicrobial Resistance Rates of E. Faecalis and E. Faecium Isolates (%)BacteriaAntibioticsE. faecalisE. faecium2021(n=207)2022(n=231)2023(n=262)2024(n=284)2025(n=349)2021(n=73)2022(n=110)2023(n=122)2024(n=133)2025(n=159)Penicillin G3.381.301.923.523.1584.9374.5584.3092.4289.31Ampicillin2.420.871.153.172.0179.4569.0979.5190.1586.79Gentamicin-high34.4729.8735.1133.1039.6653.4246.3650.0038.6458.49Streptomycin24.5125.6520.0026.0632.7627.4032.7333.6143.5133.96Ciprofloxacin-high24.1523.0426.5427.4635.5378.0870.0077.6987.1284.28Levofloxacin23.1922.6125.3826.0634.1075.3469.0976.8686.3684.28Erythromycin52.1754.3557.6356.3459.3182.1981.8279.3487.1279.87Nitrofurantoin0.491.731.151.411.7263.0151.8259.5067.4458.49Tetracycline77.7880.0085.8287.6885.1083.5671.8280.3391.6783.65Quinupristin/Dalfopristin76.8151.3069.2367.2569.9104.554.963.794.40Linezolid0000000000Vancomycin0000000000Tigecycline0000000000 Antimicrobial Resistance Rates of E. Faecalis and E. Faecium Isolates (%) Antimicrobial Resistance in Gram-Negative Bacteria Resistance Patterns in Enterobacterales From 2021 to 2025, Escherichia coli exhibited relatively high resistance (approximately 42–48%) to cefuroxime and ceftriaxone. Klebsiella pneumoniae demonstrated lower resistance to these agents (approximately 15–23%) compared to E. coli. β-lactam/β-lactamase inhibitor combinations retained relatively low resistance rates (generally <15%) in E. coli and K. pneumoniae. Although a transient increase in meropenem resistance were isolated in K. pneumoniae in 2021 (17.65%), rates subsequently declined. Other Enterobacterales species showed sporadic carbapenem resistance, but overall levels remained limited. E. coli exhibited relatively high fluoroquinolone resistance rates (approximately 42–47%), while K. pneumoniae (12–17%) and other species showed significantly lower resistance. Aminoglycosides (particularly amikacin) maintained high in vitro activity against all five species (resistance rates below 4% in most years). Tigecycline demonstrated consistent activity against all studied Enterobacterales throughout the surveillance period, with no resistant isolates detected (Table 9).Table 9Antimicrobial Resistance Rates of Enterobacterales Isolates (%)BacteriaAntibioticsE. coliK. pneumoniaeE. cloacaeS. marcescensK. aerogenes2021(n=1229)2022(n=1375)2023(n=1798)2024(n=1906)2025(n=2083)2021(n=862)2022(n=1243)2023(n=1884)2024(n=2054)2025(n=2061)2021(n=214)2022(n=252)2023(n=349)2024(n=378)2025(n=358)2021(n=75)2022(n=112)2023(n=101)2024(n=193)2025(n=163)2021(n=78)2022(n=66)2023(n=98)2024(n=132)2025(n=143)Amoxicillin/clavulanicacid11.9312.9013.3813.2613.6911.239.689.639.3610.4492.5087.8186.2883.3381.8266.6780.0066.6625.0010089.2988.8994.7489.7489.66Cefoperazone/sulbactam0000000000000000000000000Piperacillin/tazobactam9.2311.3711.9712.8113.4711.159.969.3010.3911.5122.9023.0222.7022.6121.630000029.4939.431.9632.0630.28Cefuroxime47.1245.8447.2242.4844.5522.118.2719.0421.2319.4545.8336.5945.13045.4610010010010010042.8627.7826.3233.3348.28Ceftazidime21.8221.0518.9916.1817.3215.5510.959.519.5410.2824.7724.2125.7923.2820.391.336.254.952.072.4530.7736.3631.6331.8229.37Ceftriaxone47.9746.5147.2843.0245.5921.0815.9116.2018.9317.0743.4826.8349.0236.6759.0912.5040.0000039.2927.7821.0528.2144.83Cefepime24.3022.3819.0317.8819.3112.539.909.5412.0511.277.514.766.905.057.8700.891.981.041.232.564.553.093.823.52Aztreonam33.3328.1322.5816.5613.5547.3735.0030.7716.9517.5323.5624.5323.2621.5523.151.454.675.262.123.1424.0037.520.0027.3721.05Ertapenem1.332.872.992.453.802.592.691.671.201.947.504.8813.733.339.09000003.57005.123.45Imipenem1.382.552.282.103.412.202.901.380.681.163.762.784.011.591.1203.771.05002.563.034.081.520.67Meropenem4.1710.641.590.662.3117.6516.675.491.693.092.302.364.982.301.490001.06024.173.751.050.88Amikacin3.091.602.672.412.983.362.651.541.611.501.401.193.150.791.9601.791.981.041.2301.521.0200Tobramycin43.3340.6332.2639.4730.2331.5825.4225.5615.2521.655.756.1310.967.477.4210.148.4112.636.355.632.0003.751.051.75Levofloxacin46.9543.0141.8243.9943.9316.8213.2712.8016.1115.4810.757.9410.898.7510.891.333.570.991.551.848.9710.617.146.8211.12Tigecycline0000000000000000000000000 Table 9Antimicrobial Resistance Rates of Enterobacterales Isolates (%)BacteriaAntibioticsE. coliK. pneumoniaeE. cloacaeS. marcescensK. aerogenes2021(n=1229)2022(n=1375)2023(n=1798)2024(n=1906)2025(n=2083)2021(n=862)2022(n=1243)2023(n=1884)2024(n=2054)2025(n=2061)2021(n=214)2022(n=252)2023(n=349)2024(n=378)2025(n=358)2021(n=75)2022(n=112)2023(n=101)2024(n=193)2025(n=163)2021(n=78)2022(n=66)2023(n=98)2024(n=132)2025(n=143)Amoxicillin/clavulanicacid11.9312.9013.3813.2613.6911.239.689.639.3610.4492.5087.8186.2883.3381.8266.6780.0066.6625.0010089.2988.8994.7489.7489.66Cefoperazone/sulbactam0000000000000000000000000Piperacillin/tazobactam9.2311.3711.9712.8113.4711.159.969.3010.3911.5122.9023.0222.7022.6121.630000029.4939.431.9632.0630.28Cefuroxime47.1245.8447.2242.4844.5522.118.2719.0421.2319.4545.8336.5945.13045.4610010010010010042.8627.7826.3233.3348.28Ceftazidime21.8221.0518.9916.1817.3215.5510.959.519.5410.2824.7724.2125.7923.2820.391.336.254.952.072.4530.7736.3631.6331.8229.37Ceftriaxone47.9746.5147.2843.0245.5921.0815.9116.2018.9317.0743.4826.8349.0236.6759.0912.5040.0000039.2927.7821.0528.2144.83Cefepime24.3022.3819.0317.8819.3112.539.909.5412.0511.277.514.766.905.057.8700.891.981.041.232.564.553.093.823.52Aztreonam33.3328.1322.5816.5613.5547.3735.0030.7716.9517.5323.5624.5323.2621.5523.151.454.675.262.123.1424.0037.520.0027.3721.05Ertapenem1.332.872.992.453.802.592.691.671.201.947.504.8813.733.339.09000003.57005.123.45Imipenem1.382.552.282.103.412.202.901.380.681.163.762.784.011.591.1203.771.05002.563.034.081.520.67Meropenem4.1710.641.590.662.3117.6516.675.491.693.092.302.364.982.301.490001.06024.173.751.050.88Amikacin3.091.602.672.412.983.362.651.541.611.501.401.193.150.791.9601.791.981.041.2301.521.0200Tobramycin43.3340.6332.2639.4730.2331.5825.4225.5615.2521.655.756.1310.967.477.4210.148.4112.636.355.632.0003.751.051.75Levofloxacin46.9543.0141.8243.9943.9316.8213.2712.8016.1115.4810.757.9410.898.7510.891.333.570.991.551.848.9710.617.146.8211.12Tigecycline0000000000000000000000000 Antimicrobial Resistance Rates of Enterobacterales Isolates (%) Resistance Rate of Non-Fermentative Gram-Negative Bacilli to Antimicrobial Agents (%) During five years, Pseudomonas aeruginosa maintained relatively low resistance rates (below 15%) to most anti-Pseudomonas β-lactams, aminoglycosides, and fluoroquinolones. while carbapenem resistance showed a gradual upward trend, reaching 13.44% for imipenem and 11.09% for meropenem by 2025. Acinetobacter baumannii consistently exhibited high resistance to multiple antimicrobial classes, including piperacillin/tazobactam, ceftazidime, cefepime, carbapenems, and fluoroquinolones (approximately 40–60%), exhibiting a significant multidrug-resistant phenotype. However, resistance to minocycline has decreased significantly over time (from 41.28% to 9.18%). Stenotrophomonas maltophilia showed intrinsic resistance to multiple β-lactam antibiotics, while levofloxacin and minocycline retain potent activity (resistance generally < 10%). Resistance to trimethoprim–sulfamethoxazole (TMP–SMX) remains relatively low (approximately 11–15%). Polymyxin B and tigecycline maintained consistent in vitro activity against P. aeruginosa and A. baumannii, with resistance rates consistently below 3%, underscoring their importance as last-resort treatment options (Table 10).Table 10Antimicrobial Resistance Rates of Non-Fermentative Gram-Negative Bacilli (%)BacteriaAntibioticsPseudomonas aeruginosaAcinetobater baumaniiStenotrophomonas maltophilia2021(n=554)2022(n=732)2023(n=1135)2024(n=1088)2025(n=1007)2021(n=499)2022(n=654)2023(n=962)2024(n=816)2025(n=549)2021(n=232)2022(n=245)2023(n=348)2024(n=411)2025(n=474)Ticarcillin/clavulanic acid10.9114.9917.5018.1321.8550.9654.8256.4448.3140.26NANANA7.1416.12Piperacillin/tazobactam1.632.142.854.163.1553.8958.1560.1055.7944.34NANANANANACefoperazone/sulbactam0000000000NANANANANACeftazidime9.098.039.339.8611.0552.7154.8957.6951.4139.2355.234.1631.9930.77NACefepime1.952.192.981.873.3251.0450.9254.1147.9737.22NANANANANAAztreonam2.44000098.592.0892.8094.1597.93NANANANANAImipenem6.938.548.908.8713.4451.5353.9857.4851.9339.05NANANANANAMeropenem2.866.267.536.4511.0952.5455.4558.2651.2539.89NANANANANAAmikacin0.910.971.060.371.10NANANANANANANANANANATobramycin02.073.312.152.6349.6952.5650.8641.2338.01NANANANANACiprofloxacin5.886.026.996.586.2952.6054.6557.449.6941.01NANANANANALevofloxacin19.7313.8416.3316.3615.3351.3051.2251.7744.9837.527.336.949.228.039.62Minocycline88.0077.2081.4679.7880.3341.2821.9917.1716.049.188.417.357.264.183.81Tigecycline0000000000NANANANANAPolymyxin B01.561.971.862.070.641.282.251.502.25NANANANANATMP–SMXRRRRR48.941.0424.7721.4520.0712.5013.9314.6614.6011.35Abbreviations: NA, not available; R, intrinsic resistance. Table 10Antimicrobial Resistance Rates of Non-Fermentative Gram-Negative Bacilli (%)BacteriaAntibioticsPseudomonas aeruginosaAcinetobater baumaniiStenotrophomonas maltophilia2021(n=554)2022(n=732)2023(n=1135)2024(n=1088)2025(n=1007)2021(n=499)2022(n=654)2023(n=962)2024(n=816)2025(n=549)2021(n=232)2022(n=245)2023(n=348)2024(n=411)2025(n=474)Ticarcillin/clavulanic acid10.9114.9917.5018.1321.8550.9654.8256.4448.3140.26NANANA7.1416.12Piperacillin/tazobactam1.632.142.854.163.1553.8958.1560.1055.7944.34NANANANANACefoperazone/sulbactam0000000000NANANANANACeftazidime9.098.039.339.8611.0552.7154.8957.6951.4139.2355.234.1631.9930.77NACefepime1.952.192.981.873.3251.0450.9254.1147.9737.22NANANANANAAztreonam2.44000098.592.0892.8094.1597.93NANANANANAImipenem6.938.548.908.8713.4451.5353.9857.4851.9339.05NANANANANAMeropenem2.866.267.536.4511.0952.5455.4558.2651.2539.89NANANANANAAmikacin0.910.971.060.371.10NANANANANANANANANANATobramycin02.073.312.152.6349.6952.5650.8641.2338.01NANANANANACiprofloxacin5.886.026.996.586.2952.6054.6557.449.6941.01NANANANANALevofloxacin19.7313.8416.3316.3615.3351.3051.2251.7744.9837.527.336.949.228.039.62Minocycline88.0077.2081.4679.7880.3341.2821.9917.1716.049.188.417.357.264.183.81Tigecycline0000000000NANANANANAPolymyxin B01.561.971.862.070.641.282.251.502.25NANANANANATMP–SMXRRRRR48.941.0424.7721.4520.0712.5013.9314.6614.6011.35Abbreviations: NA, not available; R, intrinsic resistance. Antimicrobial Resistance Rates of Non-Fermentative Gram-Negative Bacilli (%) Abbreviations: NA, not available; R, intrinsic resistance. Antimicrobial Resistance Among Community-Acquired Pathogens From 2021 to 2025, Haemophilus influenzae exhibited persistently high resistance to ampicillin (approximately 47%–62%) and TMP–SMX (approximately 60%–69%), indicating significant β-lactamase production and limited value of TMP–SMX in empirical treatment. H. influenzae exhibited relatively low resistance to amoxicillin/clavulanic acid (5–16%), though a gradual increase was observed after 2022. Resistance to cefuroxime and cefaclor showed an overall upward trend, peaking at 41.04% and 52.68%, respectively, after 2024. No resistance to cefotaxime or ofloxacin was detected in H. influenzae, and rifampicin resistance remained below 1%. Moraxella catarrhalis exhibited resistance below 6% for most tested drugs (including amoxicillin/clavulanic acid, cefuroxime, ceftazidime, fluoroquinolones, and chloramphenicol), confirming sustained clinical efficacy. However, M. catarrhalis exhibited moderate resistance to TMP–SMX (approximately 26%–38%), while maintaining consistently low resistance to tetracycline and rifampicin, presenting an overall relatively favorable susceptibility profile (Table 11).Table 11Antimicrobial Resistance Rates of Community-Acquired Pathogens (%)BacteriaAntibioticsHaemophilus influenzaeMoraxella catarrhalis2021(n=686)2022(726)2023(n=1136)2024(n=1324)2025(n=1010)2021(n=530)2022(n=525)2023(n=865)2024(n=575)2025(n=829)Ampicillin61.6449.8646.9261.3957.68NANANANANAAmoxicillin/clavulanic acid7.325.6611.9415.7913.270.750.381.991.050.60Cefuroxime23.5018.7329.4341.0434.191.133.065.946.135.46Cefotaxime0000000000Cefaclor29.3824.5239.5652.6849.452.272.0705.713.85Rifampicin0.290.690.880.680.500.380.760.460.880.12Ofloxacin0000000000TMP–SMX68.6764.6463.6460.9464.8133.0826.5926.5428.0137.65Chloramphenicol4.688.405.464.315.250.570.951.161.580.48Tetracycline3.804.138.297.555.753.214.576.264.93.98Abbreviation: NA, not available. Table 11Antimicrobial Resistance Rates of Community-Acquired Pathogens (%)BacteriaAntibioticsHaemophilus influenzaeMoraxella catarrhalis2021(n=686)2022(726)2023(n=1136)2024(n=1324)2025(n=1010)2021(n=530)2022(n=525)2023(n=865)2024(n=575)2025(n=829)Ampicillin61.6449.8646.9261.3957.68NANANANANAAmoxicillin/clavulanic acid7.325.6611.9415.7913.270.750.381.991.050.60Cefuroxime23.5018.7329.4341.0434.191.133.065.946.135.46Cefotaxime0000000000Cefaclor29.3824.5239.5652.6849.452.272.0705.713.85Rifampicin0.290.690.880.680.500.380.760.460.880.12Ofloxacin0000000000TMP–SMX68.6764.6463.6460.9464.8133.0826.5926.5428.0137.65Chloramphenicol4.688.405.464.315.250.570.951.161.580.48Tetracycline3.804.138.297.555.753.214.576.264.93.98Abbreviation: NA, not available. Antimicrobial Resistance Rates of Community-Acquired Pathogens (%) Abbreviation: NA, not available. Distribution of Multidrug-Resistant Organisms Between 2021 and 2025, the detection rates of most multidrug-resistant organisms (MDROs) exhibited significant temporal fluctuations. CRECO and CRKPN showed an overall upward trend, peaking in 2022 and 2025 respectively, with significant interannual differences (χ2=16.291 and 18.517). The proportion of CRPAE increased markedly from 9.57% (53/554) in 2021 to 19.96% (201/1007) in 2025, representing one of the most rapidly expanding MDRO categories during the surveillance period. In contrast, CRAB maintained consistently high prevalence, it exhibited a declining trend starting in 2023, decreasing from 59.67% (574/962) to 41.53% (228/549) by 2025 (χ2=48.271, P<0.001). MRSA decreased from 29.19% (261/894) to 24.53% (324/1321) during the study period. VRE were not detected in 2021–2022 but began to appear thereafter, rising to 2.76% by 2025. Although overall prevalence remained low, an upward trend was observed (Table 12 and Figure 1).Table 12Detection Rates of Multidrug-Resistant Organisms (MDROs), 2021–2025 (n, %)Pathogenic Bacteria20212022202320242025χ2PCRECO25 (2.03)61 (4.44)64 (3.56)54 (2.83)85 (4.08)16.2910.0027CRKPN28 (3.25)57 (4.59)53 (2.81)41 (2.00)68 (3.30)18.5170.0001CRPAE53 (9.57)125 (17.08)167 (14.71)160 (14.71)201 (19.96)32.3460.0001CRAB275 (55.11)366 (55.96)574 (59.67)434 (53.19)228 (41.53)48.2710.0001MASA261 (29.19)272 (29.73)438 (28.35)387 (26.88)324 (24.53)10.260.0036VRE0 (0)0 (0)4 (1.04)5 (1.20)14 (2.76)15.780.0033 Figure 1Annual detection rates of major (MDROs) from 2021 to 2025. Resistance rates were calculated using the total number of isolates of the corresponding species in each year as the denominator.Line graph showing annual detection rates of major multidrug-resistant organisms from 2021 to 2025.The x-axis is labeled 'Year' and the y-axis is labeled 'Rate' in percentage. The graph includes six curves: CRECO, CRKPN, CRPAE, CRABA, MASA and VRE. CRECO starts at 55.11 percent in 2021, peaks at 59.67 percent in 2023 and declines to 41.53 percent in 2025. CRKPN begins at 3.25 percent in 2021, peaks at 4.59 percent in 2022 and ends at 4.08 percent in 2025. CRPAE shows an increase from 9.57 percent in 2021 to 19.96 percent in 2025. CRABA maintains a high rate, starting at 55.11 percent in 2021, peaking at 59.67 percent in 2023 and decreasing to 41.53 percent in 2025. MASA decreases from 29.19 percent in 2021 to 24.53 percent in 2025. VRE is not detected in 2021 and 2022, appearing in 2023 at 0.91 percent and rising to 2.76 percent by 2025. Table 12Detection Rates of Multidrug-Resistant Organisms (MDROs), 2021–2025 (n, %)Pathogenic Bacteria20212022202320242025χ2PCRECO25 (2.03)61 (4.44)64 (3.56)54 (2.83)85 (4.08)16.2910.0027CRKPN28 (3.25)57 (4.59)53 (2.81)41 (2.00)68 (3.30)18.5170.0001CRPAE53 (9.57)125 (17.08)167 (14.71)160 (14.71)201 (19.96)32.3460.0001CRAB275 (55.11)366 (55.96)574 (59.67)434 (53.19)228 (41.53)48.2710.0001MASA261 (29.19)272 (29.73)438 (28.35)387 (26.88)324 (24.53)10.260.0036VRE0 (0)0 (0)4 (1.04)5 (1.20)14 (2.76)15.780.0033 Detection Rates of Multidrug-Resistant Organisms (MDROs), 2021–2025 (n, %) Annual detection rates of major (MDROs) from 2021 to 2025. Resistance rates were calculated using the total number of isolates of the corresponding species in each year as the denominator. Comparison of Hospital Antimicrobial Resistance Surveillance with the National Surveillance Network (CHINET) Between 2021 and 2025, the overall distribution of Gram-negative and Gram-positive bacteria in this hospital showed no statistically significant difference compared to CHINET data (P=0.195). However, the proportion of Gram-negative bacteria was slightly lower, while that of Gram-positive bacteria was slightly higher in the local environment. The prevalence rates of MRSA and CRAB showed no significant differences between the two datasets (P>0.05), indicating consistent antimicrobial resistance burdens for these pathogens at both institutional and national surveillance levels. And the detection rate of CRECO in the hospital was significantly higher than CHINET data (P=0.043, Cohen’s d=2.39), indicating a markedly increased local burden of carbapenem-resistant E. coli. Conversely, CRKPN detection rate was significantly lower than CHINET (P=0.001, Cohen’s d=–8.31), showing a marked deviation from the national surveillance trend. CRPAE data showed no significant statistical difference (P=0.301). Vancomycin resistance in E. faecium was significantly lower than CHINET (P=0.043), whereas the difference for E. faecalis was not statistically significant (P=0.058) (Table 13).Table 13Comparison of Bacterial Surveillance Data Between This Hospital and the CHINET Network (%)ParameterThis Research HospitalCHINETtPCohen’s d2021202220232024202520212022202320242025Gram-negative bacteria69.1069.6870.9072.5672.1971.1071.5072.4072.40-−1.5500.195−1.10Gram-positive bacteria 30.9030.3229.1027.4427.8128.9028.5027.6027.60-1.5500.1951.10MRSA29.1929.7328.3526.8824.5328.7028.2028.6028.00-0.2530.8150.18CRECO2.034.443.562.834.081.501.401.501.50-3.3800.0432.39CRAB55.1155.9659.6753.1941.5356.1055.3057.353.80-0.2310.8270.16CRPAE9.5717.0814.7114.7119.9616.8016.0015.815.40-−1.2300.301−0.87CRKPN3.254.592.812.003.3012.0010.5011.410.30-−11.7460.001−8.31Resistance rate of E. faecium to vancomycin 001.041.002.761.201.702.903.90-−2.8370.043−2.01Resistance rate of E. faecalis to vancomycin 0000.2000.200.200.200.20-−3.0000.058−1.73Note: - No updated data. Table 13Comparison of Bacterial Surveillance Data Between This Hospital and the CHINET Network (%)ParameterThis Research HospitalCHINETtPCohen’s d2021202220232024202520212022202320242025Gram-negative bacteria69.1069.6870.9072.5672.1971.1071.5072.4072.40-−1.5500.195−1.10Gram-positive bacteria 30.9030.3229.1027.4427.8128.9028.5027.6027.60-1.5500.1951.10MRSA29.1929.7328.3526.8824.5328.7028.2028.6028.00-0.2530.8150.18CRECO2.034.443.562.834.081.501.401.501.50-3.3800.0432.39CRAB55.1155.9659.6753.1941.5356.1055.3057.353.80-0.2310.8270.16CRPAE9.5717.0814.7114.7119.9616.8016.0015.815.40-−1.2300.301−0.87CRKPN3.254.592.812.003.3012.0010.5011.410.30-−11.7460.001−8.31Resistance rate of E. faecium to vancomycin 001.041.002.761.201.702.903.90-−2.8370.043−2.01Resistance rate of E. faecalis to vancomycin 0000.2000.200.200.200.20-−3.0000.058−1.73Note: - No updated data. Comparison of Bacterial Surveillance Data Between This Hospital and the CHINET Network (%) Note: - No updated data. Over the five-year period, the detection rates of H. influenzae and M. catarrhalis identified by our hospital consistently exceeded those reported by the CHINET. The differences were statistically significant (P = 0.003 and P = 0.002, respectively) and associated with large effect sizes (Cohen’s d = 3.95 and 5.81), indicating a substantially greater local burden of these pathogens. The proportion of H. influenzae remained relatively stable over time (approximately 7.5%–9.9%) and exceeded CHINET data in all comparable years. Similarly, M. catarrhalis detection rates remained between 4.3% and 6.7%, substantially exceeding CHINET values (≤1.6%), reflecting significant regional disparities. Conversely, S. pneumoniae were significantly lower than CHINET reported values (P=0.037, Cohen’s d=–2.28), with the local dataset showing a declining trend after 2022. Overall, these findings indicate that the epidemiological patterns of community-acquired respiratory pathogens at this institution differ significantly from CHINET data, particularly in the higher prevalence trends of H. influenzae and M. catarrhalis (Table 14).Table 14Comparison of Four Common Community-Acquired Pathogens Between This Hospital and CHINET (%)ParameterThis Research HospitalCHINETtPCohen’s d2021202220232024202520212022202320242025Haemophilus influenzae8.717.868.539.927.543.303.702.706.10–5.5850.0033.95Moraxella catarrhalis6.735.696.504.316.191.601.001.000.90–8.2200.0025.81Streptococcus pneumoniae6.746.866.754.384.268.808.208.007.90–−3.2200.037−2.28Note: - No updated data. Table 14Comparison of Four Common Community-Acquired Pathogens Between This Hospital and CHINET (%)ParameterThis Research HospitalCHINETtPCohen’s d2021202220232024202520212022202320242025Haemophilus influenzae8.717.868.539.927.543.303.702.706.10–5.5850.0033.95Moraxella catarrhalis6.735.696.504.316.191.601.001.000.90–8.2200.0025.81Streptococcus pneumoniae6.746.866.754.384.268.808.208.007.90–−3.2200.037−2.28Note: - No updated data. Comparison of Four Common Community-Acquired Pathogens Between This Hospital and CHINET (%) Note: - No updated data. Discussion This five-year surveillance study (January 2021–December 2025) provides a comprehensive overview of pathogen distribution and AMR dynamics of antimicrobial resistance in a large tertiary hospital in Southwest China. Several key findings warrant particular attention. These include the prevalence of Gram-negative bacteria, changes in carbapenem resistance over time among non-fermentative Gram-negative bacteria, and discrepancies between local surveillance data and national trends. Throughout the study period, Gram-negative bacteria accounted for over 70% of all isolates. This distribution reflects typical hospital epidemiological characteristics and aligns with national data, where Enterobacterales and non-fermentative Gram-negative bacilli dominate hospital-acquired infections. In line with global surveillance data, the range of pathogens observed in our hospital is similar to that seen internationally, with Gram-negative bacteria — particularly Enterobacterales and non-fermentative Gram-negative bacilli — remaining the main cause of healthcare-associated infections.12–14 While large multinational surveillance projects consistently report regional variations, they repeatedly identify the Enterobacterales, P. aeruginosa, and A. baumannii complex as core contributors to the contemporary antimicrobial resistance burden.15 This finding suggests that the microbial ecology observed in our hospital may be broadly consistent with global surveillance patterns. However, it is important to consider local patient characteristics and the structure of the sampling process. However, this study concluded that the primary areas for pathogen isolation in our hospital were the pediatric ward and ICUs. Isolation rates for respiratory pathogens (H. influenzae and M. catarrhalis) exceeded the national average, exhibiting a distinct regional pattern. This regional predominance may be influenced by demographic structure, patient referral patterns, and climatic characteristics specific to Southwest China, where subtropical environmental conditions could facilitate sustained respiratory pathogen transmission. E. coli and K. pneumoniae maintained consistently ranked among the leading pathogens over five consecutive years, dominating urinary tract, bloodstream, and respiratory infections. Although carbapenem resistance for these two strains remained below 5%, the local increase in carbapenem-resistant E. coli was significantly higher than national data, indicating the need for close monitoring of this concerning early warning trend. In the ATLAS global surveillance (2018–2022), CRE showed significant increases across multiple regions, with most growth originating from healthcare-associated infections—confirming that localized data may signal broader transmission patterns. Furthermore, meta-analysis evidence consistently links CRE infections to excess mortality, further confirming early containment measures even at low detection rates.16 Compared to the national average, the CRKPN detection rate in this region is lower and shows a declining trend.8 This further demonstrates that CRE epidemiology does not follow a single pattern: even within the same country, significant variations may exist. This is precisely why local surveillance data serves as a crucial complement to national aggregate data. Another significant finding of this study is the trajectory of carbapenem resistance development across different bacterial species. The local detection rate of CRECO was significantly higher than national CHINET data. Although the absolute resistance remains relatively low, this discrepancy holds epidemiological significance. Historically, the rise in CRE prevalence often begins with localized signals before evolving into widespread transmission. Therefore, the observed upward fluctuation should be regarded as a potential early warning signal that warrants continued surveillance. The persistently high prevalence of CRAB, with multi-year resistance rates exceeding 50%, aligns with domestic and international data, confirming its status as one of the most challenging hospital-acquired pathogens to control. Notably, a downward trend emerged after 2023. This may be related to changes in infection control practices or antimicrobial stewardship, although these factors were not directly evaluated in the present study. The persistently high burden of CRAB infections in this study aligns with international research data: CRAB remains one of the most challenging nosocomial pathogens to control, particularly in intensive care settings.17 Systematic reviews and meta-analyses indicate that CRAB infections correlate with increased mortality and are often associated with delayed effective treatment.18 This underscores the need for heightened vigilance regarding the clinical significance of CRAB pathogens, even as trends begin to improve.19 Notably, the downward trend observed in our hospital since 2023 is not fundamentally unique, global surveillance repeatedly demonstrates that when antibiotic selection pressure and transmission opportunities decrease, resistance levels may stabilize or undergo shifts.20,21 The most concerning finding is the sustained increase in CRPAE, which nearly doubled during the study period. This upward trend holds significant clinical importance due to the limited treatment options and high mortality associated with CRPAE infections. Unlike A. baumannii, which often spreads through clonal transmission within ICUs, P. aeruginosa resistance is more closely linked to cumulative antimicrobial exposure and adaptive resistance mechanisms.22,23 Consequently, this upward trend likely reflects sustained selection pressure from the use of anti-Pseudomonas carbapenems and combined β-lactam/β-lactamase inhibitor therapy.24–26 Without timely intervention, CRPAE could emerge as the primary carbapenem-resistant threat within our hospital. Notably, compared to CHINET, CRKPN prevalence remains relatively low and shows a declining trend. This discrepancy underscores the heterogeneity in the epidemiology of carbapenem-resistant Enterobacterales in China, where transmission is influenced by localized spread networks rather than a uniform nationwide clonal diffusion pattern. This indicates that regional epidemiology may not necessarily reflect national hotspots for KPC clonal strains, highlighting the importance of localized surveillance over reliance solely on national aggregate reports. In this study, non-fermentative Gram-negative bacilli and carbapenem-resistant strains accounted for a significantly high proportion of ICU isolates. This distribution pattern is highly prevalent in intensive care settings, where invasive medical devices, prolonged hospitalization, and widespread use of broad-spectrum antibiotics collectively facilitate the persistence of multidrug-resistant organisms in ICUs.27,28 The dynamic alternation between A. baumannii and K. pneumoniae as dominant species in the ICU environment further underscores the evolving nature of hospital antimicrobial resistance ecosystems.21 These findings highlight the necessity of developing ICU-specific infection control strategies, primarily encompassing restricted antimicrobial use, active culture surveillance, and environmental disinfection protocols.29,30 Additionally, throughout the study period, resistance rates of S. pneumoniae to macrolides remained persistently above 90%, consistent with reports from other regions in China. This sustained high resistance likely reflects prolonged outpatient macrolide exposure and the resulting selective pressure within community settings.31 The concurrent rise in oxacillin non-susceptibility is consistent with an increasing proportion of penicillin-non-susceptible pneumococci. These findings imply that the clinical utility of empirical macrolide therapy in pediatric respiratory infections may be progressively diminishing, particularly in regions with a high burden of childhood respiratory disease. The continued reliance on macrolides under such resistance conditions may compromise treatment efficacy and further accelerate resistance amplification. Notably, the detection rates of H. influenzae and M. catarrhalis at our hospital significantly exceed national averages. In this study, these pathogens were frequently detected. This observation highlights the potential influence of patient demographics and the distribution of specimen sources on the pathogen profile, which may be one of the reasons for the differences observed across studies. To better understand these patterns, further analysis incorporating detailed clinical stratification is required. However, the observed increase in second-generation cephalosporin resistance among H. influenzae presents an additional therapeutic challenge.32 Escalating resistance in key respiratory pathogens complicates empirical treatment strategies and underscores the need for region-specific pediatric antimicrobial guidelines.33 The discrepancy between this study’s surveillance data and national CHINET highlights a critical insight: antimicrobial resistance epidemiology is inherently regional.34 Substantial regional heterogeneity in antimicrobial resistance patterns has been reported across different regions of China, beyond comparisons with CHINET. In the more affluent eastern provinces, such as Zhejiang and Shanghai, a higher prevalence of CRKP has consistently been observed, primarily due to the clonal dissemination of strains that produce KPC enzymes.35,36 In contrast, studies from less developed western regions have reported lower CRKPN rates, though there has been a gradual increase in CRECO. Compared with CHINET data, CRKPN prevalence was lower in this study, while CRECO was relatively higher, although overall rates for both remained below 5%. The differences between our findings and CHINET data may reflect variations in patient populations, specimen sources, and local epidemiology. However, factors such as sociodemographic characteristics, antimicrobial use, and strain-level differences were not assessed in this study and therefore remain unclear. Notably, the dissemination of bla-KPC genes has been more prevalent in eastern China, while the emergence of bla-NDM and other resistance mechanisms may be contributing to the evolving epidemiology in western regions.37 These findings show that antimicrobial resistance in China does not follow a uniform national pattern and that regional surveillance is essential for accurately informing empirical therapy and antimicrobial stewardship strategies. The rising trends of CRPAE and CRECO underscore the need for early containment measures before these pathogens become entrenched. Conversely, a decline in CRAB prevalence was observed after 2023. While this trend may be influenced by changes in clinical practice or infection control measures, these factors were not directly evaluated in this study.38 While national surveillance systems like CHINET provide essential macro-level guidance, empirical treatment decisions must be grounded in locally specific surveillance data.39 In addition, the study period overlapped with the COVID-19 pandemic, which may have influenced hospital admission patterns, patient composition, and antimicrobial use. These factors could have affected the distribution of pathogens and resistance trends observed in this study and should be considered when interpreting the results. This study has several limitations. It was conducted in a single tertiary hospital, which may limit the generalizability of the findings to other regions. Molecular typing and resistance mechanism data were not available, so potential clonal spread could not be assessed. Antimicrobial consumption data were also unavailable, which limits the ability to examine the relationship between antibiotic use and resistance trends. As this was a retrospective surveillance study based on routinely collected data, no formal sample size or power calculation was performed. Despite these limitations, the large sample size and five-year study period provide a solid basis for understanding resistance trends in Southwest China. Conclusion This study describes antimicrobial resistance patterns in a large tertiary hospital in Southwest China over a five-year period. Gram-negative bacteria were predominant. CRPAE showed a sustained increase, while CRAB remained common despite a decline after 2023. Although CRECO and CRKPN rates were generally below 5%, CRECO warrants continued surveillance within the local context. These findings have practical clinical relevance. The increase in CRPAE suggests the need for more cautious use of anti-Pseudomonas agents and stronger antimicrobial stewardship, particularly in ICU settings. The consistently high resistance of Streptococcus pneumoniae to macrolides indicates that empirical treatment for respiratory infections, especially in children, may need to be reconsidered. In addition, the high prevalence of respiratory pathogens such as Haemophilus influenzae and Moraxella catarrhalis supports the use of region-specific empirical therapy and targeted infection control measures. Overall, these results highlight the importance of local surveillance data in informing clinical decisions and improving antimicrobial use.